Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Heterozygous LHX3 mutations may lead to a mild phenotype of combined pituitary hormone deficiency.

Jullien N, Romanet P, Philippon M, Quentien MH, Beck-Peccoz P, Bergada I, Odent S, Reynaud R, Barlier A, Saveanu A, Brue T, Castinetti F.

Eur J Hum Genet. 2018 Sep 27. doi: 10.1038/s41431-018-0264-6. [Epub ahead of print]

PMID:
30262920
2.

Pasireotide is more effective than octreotide, alone or combined with everolimus on human meningioma in vitro.

Graillon T, Romano D, Defilles C, Lisbonis C, Saveanu A, Figarella-Branger D, Roche PH, Fuentes S, Chinot O, Dufour H, Barlier A.

Oncotarget. 2017 Jul 24;8(33):55361-55373. doi: 10.18632/oncotarget.19517. eCollection 2017 Aug 15.

3.

Lessons from monogenic causes of growth hormone deficiency.

Brue T, Saveanu A, Jullien N, Fauquier T, Castinetti F, Enjalbert A, Barlier A, Reynaud R.

Ann Endocrinol (Paris). 2017 Jun;78(2):77-79. doi: 10.1016/j.ando.2017.04.001. Epub 2017 May 5. Review.

PMID:
28483366
4.

Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?

Mohamed A, Romano D, Saveanu A, Roche C, Albertelli M, Barbieri F, Brue T, Niccoli P, Delpero JR, Garcia S, Ferone D, Florio T, Moutardier V, Poizat F, Barlier A, Gerard C.

Oncotarget. 2017 Jun 20;8(25):41044-41063. doi: 10.18632/oncotarget.17008.

5.

Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review.

Graillon T, Romano D, Defilles C, Saveanu A, Mohamed A, Figarella-Branger D, Roche PH, Fuentes S, Chinot O, Dufour H, Barlier A.

J Neurosurg. 2017 Sep;127(3):660-669. doi: 10.3171/2016.8.JNS16995. Epub 2016 Dec 16.

PMID:
27982767
6.

MECHANISMS IN ENDOCRINOLOGY: An update in the genetic aetiologies of combined pituitary hormone deficiency.

Castinetti F, Reynaud R, Saveanu A, Jullien N, Quentien MH, Rochette C, Barlier A, Enjalbert A, Brue T.

Eur J Endocrinol. 2016 Jun;174(6):R239-47. doi: 10.1530/EJE-15-1095. Epub 2016 Jan 5. Review.

PMID:
26733480
7.

Identifying the Deleterious Effect of Rare LHX4 Allelic Variants, a Challenging Issue.

Rochette C, Jullien N, Saveanu A, Caldagues E, Bergada I, Braslavsky D, Pfeifer M, Reynaud R, Herman JP, Barlier A, Brue T, Enjalbert A, Castinetti F.

PLoS One. 2015 May 8;10(5):e0126648. doi: 10.1371/journal.pone.0126648. eCollection 2015.

8.

Pituitary stalk interruption and olfactory bulbs aplasia/hypoplasia in a man with Kallmann syndrome and reversible gonadotrope and somatotrope deficiencies.

Sarfati J, Saveanu A, Young J.

Endocrine. 2015 Aug;49(3):865-6. doi: 10.1007/s12020-014-0475-8. Epub 2014 Nov 9. No abstract available.

PMID:
25381604
9.

Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.

Mohamed A, Blanchard MP, Albertelli M, Barbieri F, Brue T, Niccoli P, Delpero JR, Monges G, Garcia S, Ferone D, Florio T, Enjalbert A, Moutardier V, Schonbrunn A, Gerard C, Barlier A, Saveanu A.

Endocr Relat Cancer. 2014 Oct;21(5):691-704. doi: 10.1530/ERC-14-0086. Epub 2014 Jul 10.

PMID:
25012983
10.

Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies.

Barbieri F, Albertelli M, Grillo F, Mohamed A, Saveanu A, Barlier A, Ferone D, Florio T.

Drug Discov Today. 2014 Apr;19(4):458-68. doi: 10.1016/j.drudis.2013.10.015. Epub 2013 Oct 27. Review.

PMID:
24171952
11.

Targeting dopamine receptors subtype 2 (D2DR) in pheochromocytomas: head-to-head comparison between in vitro and in vivo findings.

Saveanu A, Sebag F, Guillet B, Archange C, Essamet W, Barlier A, Palazzo FF, Taïeb D.

J Clin Endocrinol Metab. 2013 Dec;98(12):E1951-5. doi: 10.1210/jc.2013-2269. Epub 2013 Sep 5.

PMID:
24009136
12.

Unilateral agenesis of internal carotid artery associated with congenital combined pituitary hormone deficiency and pituitary stalk interruption without HESX1, LHX4 or OTX2 mutation: a case report.

Lamine F, Kanoun F, Chihaoui M, Saveanu A, Menif E, Barlier A, Enjalbert A, Brue T, Slimane H.

Pituitary. 2012 Dec;15 Suppl 1:S81-6. doi: 10.1007/s11102-012-0411-y.

PMID:
22797803
13.

Genetic causes of combined pituitary hormone deficiencies in humans.

Castinetti F, Reynaud R, Saveanu A, Barlier A, Brue T.

Ann Endocrinol (Paris). 2012 Apr;73(2):53-5. doi: 10.1016/j.ando.2012.03.025. Epub 2012 Apr 21. Review.

PMID:
22521856
14.

PROKR2 variants in multiple hypopituitarism with pituitary stalk interruption.

Reynaud R, Jayakody SA, Monnier C, Saveanu A, Bouligand J, Guedj AM, Simonin G, Lecomte P, Barlier A, Rondard P, Martinez-Barbera JP, Guiochon-Mantel A, Brue T.

J Clin Endocrinol Metab. 2012 Jun;97(6):E1068-73. doi: 10.1210/jc.2011-3056. Epub 2012 Mar 30.

PMID:
22466334
15.

Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion.

Cuny T, Mohamed A, Graillon T, Roche C, Defilles C, Germanetti AL, Couderc B, Figarella-Branger D, Enjalbert A, Barlier A, Saveanu A.

Mol Cell Endocrinol. 2012 May 15;355(1):106-13. doi: 10.1016/j.mce.2012.01.026. Epub 2012 Feb 14.

PMID:
22348806
16.

Case seminar: a young female with acute hyponatremia and a sellar mass.

Pekic S, Doknic M, Miljic D, Saveanu A, Reynaud R, Barlier A, Brue T, Popovic V.

Endocrine. 2011 Dec;40(3):325-31. doi: 10.1007/s12020-011-9516-8. Epub 2011 Aug 24.

PMID:
21863341
17.

Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.

Gatto F, Barbieri F, Gatti M, Wurth R, Schulz S, Ravetti JL, Zona G, Culler MD, Saveanu A, Giusti M, Minuto F, Hofland LJ, Ferone D, Florio T.

Clin Endocrinol (Oxf). 2012 Mar;76(3):407-14. doi: 10.1111/j.1365-2265.2011.04200.x.

PMID:
21848909
18.

Physiopathology of somatolactotroph cells: from transduction mechanisms to cotargeting therapy.

Cuny T, Gerard C, Saveanu A, Barlier A, Enjalbert A.

Ann N Y Acad Sci. 2011 Mar;1220:60-70. doi: 10.1111/j.1749-6632.2010.05924.x. Review.

PMID:
21388404
19.

Expression of somatostatin receptors, dopamine D₂ receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas.

Saveanu A, Muresan M, De Micco C, Taieb D, Germanetti AL, Sebag F, Henry JF, Brunaud L, Enjalbert A, Weryha G, Barlier A.

Endocr Relat Cancer. 2011 Mar 21;18(2):287-300. doi: 10.1530/ERC-10-0175. Print 2011 Apr.

PMID:
21335363
20.

Detection of genetic hypopituitarism in an adult population of idiopathic pituitary insufficiency patients with growth hormone deficiency.

Nyström HF, Saveanu A, Barbosa EJ, Barlier A, Enjalbert A, Glad C, Palming J, Johannsson G, Brue T.

Pituitary. 2011 Sep;14(3):208-16. doi: 10.1007/s11102-010-0278-8.

PMID:
21132537

Supplemental Content

Loading ...
Support Center